Cycling Toward Progress: Ribociclib, a CDK 4/6 Inhibitor for Breast Cancer

Spring, L., Bardia, A.
The American Association for Cancer Research (AACR)
Published 2018
Publication Date:
2018-07-03
Publisher:
The American Association for Cancer Research (AACR)
Print ISSN:
1078-0432
Electronic ISSN:
1557-3265
Topics:
Medicine
Published by:
_version_ 1836398995199492096
autor Spring, L., Bardia, A.
beschreibung Ribociclib is an orally active, highly selective inhibitor of cyclin-dependent kinase (CDK) 4 and 6. It is the second CDK 4/6 inhibitor approved for hormone receptor–positive breast cancer. The addition of ribociclib to an aromatase inhibitor has resulted in marked improvements in progression-free survival for patients with metastatic breast cancer. Clin Cancer Res; 24(13); 2981–3. ©2018 AACR . See related article by Shah et al., p. 2999
citation_standardnr 6297177
datenlieferant ipn_articles
feed_id 9363
feed_publisher The American Association for Cancer Research (AACR)
feed_publisher_url http://www.aacr.org/
insertion_date 2018-07-03
journaleissn 1557-3265
journalissn 1078-0432
publikationsjahr_anzeige 2018
publikationsjahr_facette 2018
publikationsjahr_intervall 7984:2015-2019
publikationsjahr_sort 2018
publisher The American Association for Cancer Research (AACR)
quelle Clinical Cancer Research
relation http://clincancerres.aacrjournals.org/cgi/content/short/24/13/2981?rss=1
search_space articles
shingle_author_1 Spring, L., Bardia, A.
shingle_author_2 Spring, L., Bardia, A.
shingle_author_3 Spring, L., Bardia, A.
shingle_author_4 Spring, L., Bardia, A.
shingle_catch_all_1 Cycling Toward Progress: Ribociclib, a CDK 4/6 Inhibitor for Breast Cancer
Ribociclib is an orally active, highly selective inhibitor of cyclin-dependent kinase (CDK) 4 and 6. It is the second CDK 4/6 inhibitor approved for hormone receptor–positive breast cancer. The addition of ribociclib to an aromatase inhibitor has resulted in marked improvements in progression-free survival for patients with metastatic breast cancer. Clin Cancer Res; 24(13); 2981–3. ©2018 AACR . See related article by Shah et al., p. 2999
Spring, L., Bardia, A.
The American Association for Cancer Research (AACR)
1078-0432
10780432
1557-3265
15573265
shingle_catch_all_2 Cycling Toward Progress: Ribociclib, a CDK 4/6 Inhibitor for Breast Cancer
Ribociclib is an orally active, highly selective inhibitor of cyclin-dependent kinase (CDK) 4 and 6. It is the second CDK 4/6 inhibitor approved for hormone receptor–positive breast cancer. The addition of ribociclib to an aromatase inhibitor has resulted in marked improvements in progression-free survival for patients with metastatic breast cancer. Clin Cancer Res; 24(13); 2981–3. ©2018 AACR . See related article by Shah et al., p. 2999
Spring, L., Bardia, A.
The American Association for Cancer Research (AACR)
1078-0432
10780432
1557-3265
15573265
shingle_catch_all_3 Cycling Toward Progress: Ribociclib, a CDK 4/6 Inhibitor for Breast Cancer
Ribociclib is an orally active, highly selective inhibitor of cyclin-dependent kinase (CDK) 4 and 6. It is the second CDK 4/6 inhibitor approved for hormone receptor–positive breast cancer. The addition of ribociclib to an aromatase inhibitor has resulted in marked improvements in progression-free survival for patients with metastatic breast cancer. Clin Cancer Res; 24(13); 2981–3. ©2018 AACR . See related article by Shah et al., p. 2999
Spring, L., Bardia, A.
The American Association for Cancer Research (AACR)
1078-0432
10780432
1557-3265
15573265
shingle_catch_all_4 Cycling Toward Progress: Ribociclib, a CDK 4/6 Inhibitor for Breast Cancer
Ribociclib is an orally active, highly selective inhibitor of cyclin-dependent kinase (CDK) 4 and 6. It is the second CDK 4/6 inhibitor approved for hormone receptor–positive breast cancer. The addition of ribociclib to an aromatase inhibitor has resulted in marked improvements in progression-free survival for patients with metastatic breast cancer. Clin Cancer Res; 24(13); 2981–3. ©2018 AACR . See related article by Shah et al., p. 2999
Spring, L., Bardia, A.
The American Association for Cancer Research (AACR)
1078-0432
10780432
1557-3265
15573265
shingle_title_1 Cycling Toward Progress: Ribociclib, a CDK 4/6 Inhibitor for Breast Cancer
shingle_title_2 Cycling Toward Progress: Ribociclib, a CDK 4/6 Inhibitor for Breast Cancer
shingle_title_3 Cycling Toward Progress: Ribociclib, a CDK 4/6 Inhibitor for Breast Cancer
shingle_title_4 Cycling Toward Progress: Ribociclib, a CDK 4/6 Inhibitor for Breast Cancer
timestamp 2025-06-30T23:35:56.101Z
titel Cycling Toward Progress: Ribociclib, a CDK 4/6 Inhibitor for Breast Cancer
titel_suche Cycling Toward Progress: Ribociclib, a CDK 4/6 Inhibitor for Breast Cancer
topic WW-YZ
uid ipn_articles_6297177